Atlas Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Atlas Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	-$4.23K	–	913
2022 Q2	$4.23K	Hold	300	–	–	﹤0.01%	867
2022 Q1	$7.27K	Hold	300	–	–	﹤0.01%	750
2021 Q4	$7K	Hold	300	–	–	﹤0.01%	768
2021 Q3	$4.98K	Hold	300	–	–	﹤0.01%	811
2021 Q2	$7.32K	Hold	300	–	–	﹤0.01%	787
2021 Q1	$7.74K	Buy	+300	New	+$13.2K	﹤0.01%	707

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Atlas Capital Advisors's ACAD Position: Q3 2022 in Review

Atlas Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 300 shares — an estimated $4.23K sold.

Atlas Capital Advisors first reported a position in ACAD in Q1 2021 and held it in 6 quarters. The position peaked at $7.74K in Q1 2021. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

Atlas Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Atlas Capital Advisors sold 300 Acadia Pharmaceuticals shares in Q3 2022, an estimated $4.23K.
Atlas Capital Advisors first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 6 quarters.
Atlas Capital Advisors's Acadia Pharmaceuticals position peaked at $7.74K in Q1 2021.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Atlas Capital Advisors's 13F filing for Q3 2022, filed 8 Nov 2022.